COMP <GO>
CRSP vs SRRK // PIOTROSKI F-SCORE QUALITY
CRISPR Therapeutics AG (NASDAQ) VS. Scholar Rock Holding Corporation (NASDAQ) • 15-METRIC TALLY: CRSP 3
— SRRK 6
▲ PIOTROSKI F-SCORE QUALITY LEADER: SRRK
LAST: $49.99 (0.00%) • MKT CAP: $4.83B
piotroski-score
4/9
LAST: $43.98 (+2.49%) • MKT CAP: $5.23B
piotroski-score
5/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRSP VS. SRRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRSP | SRRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.60% | -35.00% | +4.40 | CRSP | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.59% | -5.59% | -1.00 | SRRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 7.70% | -72.70 | SRRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.97 | 13.67 | -5.70 | SRRK | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 5/9 | -1.00 | SRRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.0 | 44.5 | -0.50 | SRRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 1.02 | +0.10 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 32.0x | -4.00 | CRSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.83B | $5.23B | -$392.1M | SRRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRSP REV | SRRK REV | CRSP GROSS % | SRRK GROSS % | CRSP FCF | SRRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $1.08B | — | — | -$345.9M | -$300.6M |
| FY 2024 | $37.3M | $705.8M | — | — | -$144.7M | -$201.0M |
| FY 2023 | $371.2M | $479.6M | — | — | -$277.1M | -$145.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRSP // BETA 1.12
SRRK // BETA 1.02